Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia.

Leuk Lymphoma

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Published: November 2021

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556225PMC
http://dx.doi.org/10.1080/10428194.2021.1929959DOI Listing

Publication Analysis

Top Keywords

moxetumomab pasudotox
4
pasudotox re-treatment
4
re-treatment heavily-pretreated
4
heavily-pretreated relapsed
4
relapsed hairy
4
hairy cell
4
cell leukemia
4
moxetumomab
1
re-treatment
1
heavily-pretreated
1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!